Loading...

SeaStar Medical Holding Corporation

ICUCW•NASDAQ
Healthcare
Biotechnology
$0.02
$0.003(16.70%)

SeaStar Medical Holding Corporation (ICUCW) Stock Overview

Explore SeaStar Medical Holding Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.5/100

Key Financials

Market Cap4.6M
P/E Ratio-0.23
EPS (TTM)N/A
ROE6.02%

AI Price Forecasts

1 Week$0.03
1 Month$0.06
3 Months$0.00
1 Year Target$0.01

ICUCW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of SeaStar Medical Holding Corporation (ICUCW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.23 and a market capitalization of 4.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ICUCWStats details for ICUCW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ICUCWAnalyst Recommendations details for ICUCW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

CEO

Mr. David A. Green CPA, M.B.A.

Employees

19

Headquarters

3513 Brighton Boulevard, Denver, CO

Founded

1970

Frequently Asked Questions

;